Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AXSM Stock Forecast 2025-2026
$105.07
Current Price
$5.17B
Market Cap
Buy 18
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AXSM Price Targets
+99.9%
To High Target of $210.00
+71.3%
To Median Target of $180.00
+39.0%
To Low Target of $146.00
AXSM Price Momentum
-2.3%
1 Week Change
-0.3%
1 Month Change
+39.7%
1 Year Change
+24.2%
Year-to-Date Change
-24.5%
From 52W High of $139.13
+63.9%
From 52W Low of $64.11
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Axsome (AXSM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AXSM and similar high-potential opportunities.
Latest AXSM Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, AXSM has a bullish consensus with a median price target of $180.00 (ranging from $146.00 to $210.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $105.07, the median forecast implies a 71.3% upside. This outlook is supported by 18 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 99.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AXSM Analyst Ratings
18
Buy
0
Hold
0
Sell
AXSM Price Target Range
Low
$146.00
Average
$180.00
High
$210.00
Current: $105.07
Latest AXSM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AXSM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $180.00 |
| May 7, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $180.00 |
| May 6, 2025 | Baird | Joel Beatty | Outperform | Maintains | $162.00 |
| May 6, 2025 | Wells Fargo | Cerena Chen | Overweight | Maintains | $165.00 |
| Apr 29, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $193.00 |
| Apr 7, 2025 | Jefferies | Andrew Tsai | Buy | Initiates | $200.00 |
| Apr 3, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $200.00 |
| Apr 1, 2025 | Needham | Ami Fadia | Buy | Reiterates | $153.00 |
| Mar 27, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $216.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $200.00 |
| Mar 3, 2025 | Needham | Ami Fadia | Buy | Reiterates | $153.00 |
| Mar 3, 2025 | Baird | Joel Beatty | Outperform | Maintains | $160.00 |
| Feb 27, 2025 | Morgan Stanley | Vikram Purohit | Overweight | Maintains | $190.00 |
| Feb 26, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $212.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $200.00 |
| Feb 24, 2025 | Needham | Ami Fadia | Buy | Reiterates | $153.00 |
| Feb 20, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $200.00 |
| Feb 19, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $200.00 |
| Feb 19, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $192.00 |
| Feb 19, 2025 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $153.00 |
Axsome Therapeutics Inc. (AXSM) Competitors
The following stocks are similar to Axsome based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Axsome Therapeutics Inc. (AXSM) Financial Data
Axsome Therapeutics Inc. has a market capitalization of $5.17B with a P/E ratio of -17.5x. The company generates $432.16M in trailing twelve-month revenue with a -64.4% profit margin.
Revenue growth is +62.0% quarter-over-quarter, while maintaining an operating margin of -45.7% and return on equity of -282.2%.
Valuation Metrics
Market Cap
$5.17B
Enterprise Value
$5.08B
P/E Ratio
-17.5x
PEG Ratio
-48.6x
Price/Sales
12.0x
Growth & Margins
Revenue Growth (YoY)
+62.0%
Gross Margin
+91.9%
Operating Margin
-45.7%
Net Margin
-64.4%
EPS Growth
+62.0%
Financial Health
Cash/Price Ratio
+5.8%
Current Ratio
2.0x
Debt/Equity
397.0x
ROE
-282.2%
ROA
-26.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Axsome Therapeutics Inc. (AXSM) Business Model
About Axsome Therapeutics Inc.
What They Do
Develops therapies for central nervous system disorders.
Business Model
Axsome Therapeutics focuses on developing and commercializing innovative therapies for CNS disorders, generating revenue through the sale of its pharmaceutical products once they receive regulatory approval. The company invests in a robust pipeline of clinical and preclinical candidates, aiming to address significant unmet medical needs in areas such as depression and migraines.
Additional Information
With a commitment to innovation and efficacy, Axsome utilizes novel mechanisms of action to enhance treatment options for patients. The company actively engages in strategic collaborations and cutting-edge research to improve healthcare solutions globally, positioning itself as a key player in the biotechnology industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
683
CEO
Dr. Herriot Tabuteau M.D.
Country
United States
IPO Year
2015
Website
www.axsome.comAxsome Therapeutics Inc. (AXSM) Latest News & Analysis
Latest News
Quick Summary
Axsome Therapeutics (AXSM) is featured in a Motley Fool Scoreboard episode, offering insights into market trends and potential investment opportunities.
Why It Matters
The focus on Axsome Therapeutics highlights potential market trends and investment opportunities, indicating shifts in biotech valuations that could impact investor strategies.
Source: The Motley Fool
Market Sentiment:
Positive
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
11 days ago
Quick Summary
Axsome Therapeutics has secured a $570 million term loan and revolving credit facility from Blackstone, retiring its previous loan with Hercules Capital.
Why It Matters
Axsome's $570 million loan from Blackstone enhances liquidity and financial stability, allowing for potential growth and investment in CNS treatments, which can impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Historically, the stock market yields solid long-term returns. Investors may enhance gains by selecting stocks expected to outperform the market.
Why It Matters
The excerpt highlights the historical resilience of the market and suggests that savvy stock selection can yield superior returns, influencing investment strategies and confidence.
Source: The Motley Fool
Market Sentiment:
Positive
3 Monster Stocks in the Making
12 days ago
Quick Summary
The excerpt suggests reflecting on the historical performance of currently successful stocks over the past 20 to 30 years, indicating their long-term growth potential.
Why It Matters
Reflecting on historical stock performance can highlight trends, identify potential future winners, and inform investment strategies based on long-term growth patterns.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will hold its Q1 2025 Earnings Conference Call on May 5, 2025, at 8:00 AM ET. Key company executives will participate.
Why It Matters
Axsome's Q1 earnings call indicates potential insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
19 days ago
Quick Summary
Axsome Therapeutics reported Q1 2025 net revenue of $121.5M, up 62% YoY. AUVELITY sales rose 80% to $96.2M, and SYMBRAVO is set for June launch. Multiple NDA submissions planned for 2025.
Why It Matters
Axsome Therapeutics shows robust revenue growth and successful product launches, indicating strong market demand and a promising pipeline, which could drive stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AXSM Stock
What is Axsome Therapeutics Inc.'s (AXSM) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Axsome Therapeutics Inc. (AXSM) has a median price target of $180.00. The highest price target is $210.00 and the lowest is $146.00.
Is AXSM stock a good investment in 2025?
According to current analyst ratings, AXSM has 18 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $105.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AXSM stock?
Wall Street analysts predict AXSM stock could reach $180.00 in the next 12 months. This represents a 71.3% increase from the current price of $105.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Axsome Therapeutics Inc.'s business model?
Axsome Therapeutics focuses on developing and commercializing innovative therapies for CNS disorders, generating revenue through the sale of its pharmaceutical products once they receive regulatory approval. The company invests in a robust pipeline of clinical and preclinical candidates, aiming to address significant unmet medical needs in areas such as depression and migraines.
What is the highest forecasted price for AXSM Axsome Therapeutics Inc.?
The highest price target for AXSM is $210.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 99.9% increase from the current price of $105.07.
What is the lowest forecasted price for AXSM Axsome Therapeutics Inc.?
The lowest price target for AXSM is $146.00 from at , which represents a 39.0% increase from the current price of $105.07.
What is the overall AXSM consensus from analysts for Axsome Therapeutics Inc.?
The overall analyst consensus for AXSM is bullish. Out of 23 Wall Street analysts, 18 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $180.00.
How accurate are AXSM stock price projections?
Stock price projections, including those for Axsome Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 2:56 AM UTC